Literature DB >> 15327747

Probucol as a potent inhibitor of oxygen radical-induced lipid peroxidation and DNA damage: in vitro studies.

Mohammad Iqbal1, Som Datta Sharma, Shigeru Okada.   

Abstract

Probucol, a clinically used cholesterol lowering and antioxidant drug, was investigated for possible protection against lipid peroxidation and DNA damage induced by iron nitrilotriacetate (Fe-NTA) plus hydrogen peroxide (H2O2). Fe-NTA is a potent nephrotoxic agent and induces acute and subacute renal proximal tubular necrosis by catalyzing the decomposition of H2O2-derived production of hydroxyl radicals, which are known to cause lipid peroxidation and DNA damage. Fe-NTA is associated with a high incidence of renal adenocarcinoma in rodents. Lipid peroxidation and DNA damage are the principal manifestation of Fe-NTA induced toxicity, which could be mitigated by probucol. Incubation of renal microsomal membrane and/or calf thymus DNA with H2O2 (40 mM) in the presence of Fe-NTA (0.1 mM) induces renal microsomal lipid peroxidation and DNA damage to about 2.4-fold and 5.9-fold, respectively, as compared to control (P < 0.05). Induction of renal microsomal lipid peroxidation and DNA damage was inhibited by probucol in a concentration-dependent manner. In lipid peroxidation protection studies, probucol treatment showed a concentration-dependent inhibition (10-34% inhibition; P < 0.05) of Fe-NTA plus H2O2-induced lipid peroxidation as measured by thiobarbituric acid reacting species' (TBARS) formation in renal microsomes. Similarly, in DNA damage protection studies, probucol treatment also showed a concentration-dependent strong inhibition (36-71% inhibition; P < 0.05) of DNA damage. From these studies, it was concluded that probucol inhibits peroxidation of microsomal membrane lipids and DNA damage induced by Fe-NTA plus H2O2. However, because the lipid peroxidation and DNA damage studied here are regarded as early markers of carcinogenesis, we suggest that probucol may be developed as a cancer chemopreventive agent against renal carcinogenesis and other adverse effects of Fe-NTA exposure in experimental animals, in addition to being a cholesterol-lowering drug, useful for the control of hypercholestrolemia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15327747     DOI: 10.1179/135100004225005174

Source DB:  PubMed          Journal:  Redox Rep        ISSN: 1351-0002            Impact factor:   4.412


  6 in total

1.  Strobilanthes crispus attenuates renal carcinogen, iron nitrilotriacetate (Fe-NTA)-mediated oxidative damage of lipids and DNA.

Authors:  Mohammad Iqbal; Muhammad Dawood Shah; Chau Ann Lie; Chin Kim San
Journal:  Mol Cell Biochem       Date:  2010-04-08       Impact factor: 3.396

2.  Probucol promotes osteoblasts differentiation and prevents osteoporosis development through reducing oxidative stress.

Authors:  Zhou-Shan Tao; Tian-Lin Li; Shan Wei
Journal:  Mol Med       Date:  2022-06-28       Impact factor: 6.376

3.  Probucol modulates iron nitrilotriacetate (Fe-NTA)-dependent renal carcinogenesis and hyperproliferative response: diminution of oxidative stress.

Authors:  Mohammad Iqbal; Yasumasa Okazaki; Shigeru Okada
Journal:  Mol Cell Biochem       Date:  2007-05-09       Impact factor: 3.396

4.  Probucol attenuates cyclophosphamide-induced oxidative apoptosis, p53 and Bax signal expression in rat cardiac tissues.

Authors:  Yosef A Asiri
Journal:  Oxid Med Cell Longev       Date:  2010-09-01       Impact factor: 6.543

5.  Probucol ameliorates renal injury in diabetic nephropathy by inhibiting the expression of the redox enzyme p66Shc.

Authors:  Shikun Yang; Li Zhao; Yachun Han; Yu Liu; Chao Chen; Ming Zhan; Xiaofen Xiong; Xuejing Zhu; Li Xiao; Chun Hu; Fuyou Liu; Zhiguang Zhou; Yashpal S Kanwar; Lin Sun
Journal:  Redox Biol       Date:  2017-07-04       Impact factor: 11.799

6.  Enhanced Antioxidant Effects of the Anti-Inflammatory Compound Probucol When Released from Mesoporous Silica Particles.

Authors:  Michael Lau; Benjamin Sealy; Valery Combes; Marco Morsch; Alfonso E Garcia-Bennett
Journal:  Pharmaceutics       Date:  2022-02-24       Impact factor: 6.525

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.